NasdaqGS:JAZZPharmaceuticals
Will New Epidiolex and Xywav Data Shift Jazz Pharmaceuticals' (JAZZ) Neuroscience Value Narrative?
Jazz Pharmaceuticals has already presented six new clinical data abstracts on Epidiolex and Xywav at the 2026 American Academy of Neurology Annual Meeting in Chicago, including an oral presentation from the ongoing EpiCom Phase 3b/4 study in tuberous sclerosis complex–associated seizures.
The new findings, highlighting caregiver- and clinician-reported behavioral improvements with Epidiolex and enhanced functional outcomes with higher-dose Xywav, underscore how Jazz is aiming to deepen the...